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Abstract
Background: Immunity to infections caused by Streptococcus pneumoniae is dependent on complement. There are wide
variations in sensitivity to complement between S. pneumoniae strains that could affect their ability to cause invasive
infections. Although capsular serotype is one important factor causing differences in complement resistance between
strains, there is also considerable other genetic variation between S. pneumoniae strains that may affect complement-
mediated immunity. We have therefore investigated whether genetically distinct S. pneumoniae strains with the same
capsular serotype vary in their sensitivity to complement mediated immunity.
Methodology and Principal Findings: C3b/iC3b deposition and neutrophil association were measured using flow
cytometry assays for S. pneumoniae strains with different genetic backgrounds for each of eight capsular serotypes. For
some capsular serotypes there was marked variation in C3b/iC3b deposition between different strains that was
independent of capsule thickness and correlated closely to susceptibility to neutrophil association. C3b/iC3b deposition
results also correlated weakly with the degree of IgG binding to each strain. However, the binding of C1q (the first
component of the classical pathway) correlated more closely with C3b/iC3b deposition, and large differences remained in
complement sensitivity between strains with the same capsular serotype in sera in which IgG had been cleaved with IdeS.
Conclusions: These data demonstrate that bacterial factors independent of the capsule and recognition by IgG have strong
effects on the susceptibility of S. pneumoniae to complement, and could therefore potentially account for some of the
differences in virulence between strains.
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Introduction
The nasopharyngeal commensal Streptococcus pneumoniae com-
monly causes severe infections such as pneumonia, meningitis and
septicaemia. Immunity to S. pneumoniae is highly dependent on the
complement system [1,2,3,4], a series of host serum and cell
surface proteins organised into three enzyme cascades termed the
classical, alternative and mannan binding lectin (MBL) pathways.
The classical pathway is activated by specific antibody [5], and by
recognition of S. pneumoniae cell wall phosphorylcholine (PC) by
natural IgM or the serum pentraxin proteins C reactive protein
(CRP) and serum amyloid P (SAP), or by binding of the capsule to
the lectin SIGN-R1 [2,6,7,8]. Classical pathway activation results
in binding of C1q to the bacterial surface and the formation of the
classical pathway C3 convertase [5]. MBL binds poorly to S.
pneumoniae and may have little effect on complement activation by
S. pneumoniae [2,9]. The alternative pathway is spontaneously
activated unless the target cell is coated in sialic acid or
complement inhibitory proteins such as factor H (FH) [5].
Complement activation leads to C3b deposition on the bacterial
surface which is further processed to iC3b, both of which act as
opsonins for phagocytosis [5]. Complement activation also aids the
inflammatory response through release of anaphylaxins such as
C5a and improves adaptive immune response to S. pneumoniae
through direct stimulation of B cells by C3d. As a consequence
neutrophil phagocytosis and killing of S. pneumoniae and optimum
antibody responses are highly dependent on complement activity
[10,11].
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further demonstrated by the multiple mechanisms of complement
evasion that S. pneumoniae has evolved. The extracellular
polysaccharide capsule of S. pneumoniae inhibits classical pathway
and alternative pathway activity and inhibits degradation of C3b
to iC3b [12]. Various S. pneumoniae proteins also inhibit
complement activity, including the choline binding surface
proteins PspA and PspC, the toxin pneumolysin, pneumococcal
histidine triad proteins (Pht), and the exoglycosidases NanA, BgaA,
and StrH [13,14,15,16]. PspA inhibits both alternative and
classical activity by unknown mechanisms, whereas PspC prevents
alternative pathway activity by binding the host alternative
pathway regulator protein Factor H (FH) and in some strains
the classical pathway inhibitor C4b binding protein (C4BP)
[13,14,17,18,19]. Extracellular release of pneumolysin may divert
classical pathway activity away from S. pneumoniae by binding C1q.
Inhibition of complement activity by Pht proteins depends on
serotype background and could be related to FH binding
[13,16,20]. How exoglycosidases affect complement activity is
not clear but could be due to deglycosylation of complement
protein glycoconjugates [15]. S. pneumoniae can also degrade C3
[21]) and there are probably other S. pneumoniae mechanisms of
complement evasion that have yet to be described.
Different S. pneumoniae strains vary in their sensitivity to
complement [22,23]. There are over 90 recognized capsular
serotypes related to the type, order and chemical bonds of
monosaccharide units within the polysaccharide chain and the
presence of side chains. Using capsular switched strains expressing
different capsular serotypes on the same genetic background, we
and others have demonstrated that variations between S.
pneumoniae strains in complement sensitivity is at least partially
linked to serotype [24,25,26]. In addition, during infection S.
pneumoniae can undergo phase variation between transparent
variants which have relatively thin capsules and are more sensitive
to complement and opaque phase variants which have thicker
capsules and are more complement-resistant [26]. Conversely,
antibody recognition of the capsule could increase complement
activity via activation of the classical pathway, and the sensitivity of
different S. pneumoniae capsular serotypes to anti-capsular antibody
varies. For example serotype 19F requires a greater concentration
of anti-capsular antibody to achieve similar levels of killing in an
opsonophagocytosis assays as serotypes 6B or 23F [23].
As well as the capsule there is also a surprising amount of other
genetic variation between S. pneumoniae strains. Only around 60% of
gene clustersarecommontoallstrainsandgene contentvariesupto
10% between any two strains, even between strains with the same
capsular serotype [27,28]. This genetic variation could influence
bacterial complement resistance independent of capsular serotype.
For example the expression of complement-inhibiting proteins may
vary between strains, and thereis significantallelicvariationinPspA
and PspC structure between strains that may have functional
consequences [14,29,30]. Furthermore, S. pneumoniae genetic
variation between strains includes numerous gene deletions and
insertions, with at least 41 regions of diversity (RD) containing
clustersofgenespresentonlyinrestricted strains[28,31,32,33]some
of which could influence complement activity. Recent publications
have confirmed that non-capsular genetic variation influences S.
pneumoniae complement resistance. C3b/iC3b deposition has
marked variation between different serotype 6A strains [34], and
Melin et al. showed differences in complement sensitivity between
three different genetic backgrounds expressing capsular serotypes
19F or 6B [23]. The central role of complement for immunity to S.
pneumoniae suggests these differences in complement sensitivity could
be clinically relevant, and indeed complement resistant strains have
been linked with a higher potential to cause otitis media or death
during invasive infection [34,35].
To confirm and further characterise the effects of genetic
variation independent of capsular serotype on complement-
mediated immunity we have used several clinical S. pneumoniae
isolates with different genetic backgrounds assessed by multilocus
sequence typing (MLST) [36] for eight common capsular
serotypes. Using these strains we have investigated the relationship
between antibody binding, neutrophil association, capsule thick-
ness and S. pneumoniae resistance to opsonisation with C3b/iC3b.
Results
C3b/iC3b deposition varies between S. pneumoniae
strains with the same capsular serotype
To investigate the relative importance of genetic variation
independent of capsular serotype between S. pneumoniae strains on
complement activity, C3b/iC3b deposition was assessed on 33
clinical isolates from eight different capsular serotypes that
frequently cause S. pneumoniae infections (1, 4, 14, 6A, 6B, 9V,
19F and 23F). For each serotype, three or more strains
representative of dominant sequence types (STs) identified by
MLST were chosen, with a total of 24 different STs investigated.
Five pairs of strains with the same capsular serotype and same ST
but isolated from distinct geographical areas were also included
(Table 1). There was considerable variation in the results of C3b/
iC3b deposition between the strains. When the results of C3b/
iC3b deposition were presented as a composite fluorescence index
(FI) to represent both the proportion of bacteria coated with C3b/
iC3b and the intensity of C3b/iC3b deposited, the results varied
from 9060 (for an ST162 serotype 14 strain) to 743240 (for an
ST1068 serotype 6A strain) (Table 1). For some serotypes, strains
with different STs had markedly different results (Table 1 and
Fig. 1). For example, the serotype 6B ST138 strain had markedly
higher levels of C3b/iC3b deposition than the serotype 6B ST90,
and ST273 strains (Fig. 1C, ANOVA with post hoc tests
R,0.001), and the serotype 23F ST277 strain had greater C3b/
iC3b deposition than the serotype 23F ST515 and ST36 strains
(Fig. 1D, ANOVA with post hoc tests R,0.001). Other serotypes
showed less variation in C3b/iC3b deposition between strains (eg
serotypes 1 and 4) (Fig. 1). There were also differences in C3b/
iC3b deposition for strains with the same sequence type (ST) and
with the same capsular serotype that were isolated from different
geographical backgrounds (eg ST176 serotype 6B isolates,
P,0.001 Student’s T test) (Table 1). There were no significant
differences in median C3b/iC3b deposition for each serotype
except for serotype 6A strains which had a higher median C3b/
iC3b deposition than all other serotypes (comparison to 6B strains
shown in Fig. 1B). These data demonstrate that S. pneumoniae strain
background independent of capsular serotype can be a strong
determinant of C3b/iC3b deposition, causing such large varia-
tions in results between strains with the same capsular serotype
that differences in median C3b/iC3b deposition between capsular
serotypes are obscured.
Neutrophil association correlates with the results for
C3b/iC3b deposition
To assess whether the differences in C3b/iC3b deposition
between S. pneumoniae strains had functional consequences,
neutrophil association after incubation in human serum was
measured using a flow cytometry assay. Results were expressed as
the proportion of neutrophils associated with fluorescent bacteria
which has previously been shown to be mainly due to phagocytosis
[10,12]. Neutrophil association varied significantly between S.
Streptococcus pneumoniae Complement Resistance
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associated with a ST515 serotype 23F strain and a maximum of
96% of neutrophils associated with a ST138 serotype 6B strain in
the test conditions used (Table 1). Like the C3b/iC3b deposition
results, there were large variations in neutrophil association results
between strains with the same capsular serotype and there were
large overlaps for the results of individual strains from different
serotypes (Table 1). Importantly, C3b/iC3b deposition on each S.
pneumoniae strain had a positive correlation with the neutrophil
association results (Pearson’s correlation co-efficient R
2=0.58)
(Fig. 2), demonstrating that variation in C3b/iC3b deposition
between strains was functionally important for neutrophil
mediated immunity.
Differences in C3b/iC3b deposition between strains of
the same serotype are unrelated to capsule thickness
S. pneumoniae undergoes phase variation between opaque and
transparent variants, with the latter having thinner capsule layers
[37] and higher levels of C3b/iC3b deposition [26]. Phase
variation therefore could potentially explain some of the
differences in C3b/iC3b deposition between strains with the
same capsular serotype. However, microscopic examination on
Table 1. Clinical isolates of S. pneumoniae used in this study with their ST, and the results for C3b/iC3b deposition (FI in 25%
serum), IgG binding (FI 25% human serum), C1q binding (FI 25% human serum), and neutrophil association (percentage
association in 20% human serum).
Serotype ST
Original
strain name
IgG
Binding
(FI ± SD)
a
C1q Binding
(FI ± SD)
a
C3b/iC3b
Binding
(FI ± SD)
a
% neutrophil
association
(± SD) source
b
1 306 BHN 30 11506250 43606130 2760065930 63.964.5 BHN
1 228 BHN 32 1060650 14706120 1400063260 59.863.1 BHN
1 217 BHN 166 1090640 27906265 1834064000 46.262.8 BHN
4 1222 BHN 42 1360630 15306370 4559061780 55.563.1 BHN
4 205 BHN 43 1650650 38506520 3817061720 48.763.2 BHN
4 205 n/a
c 1440680 33806625 4713069080 68.764.1 BGS
4 259 n/a 1390640 18206490 43060613090 56.463.9 BGS
6A 488 IOKOR1277-3 44706560 67006390 484860610920 65.060.9 BGS
6A 490 IOKOR1373-9 18006340 37406330 31323069730 75.762.2 BGS
6A 518 IOKOR801-2 20006460 46906390 30729068370 47.164.2 BGS
6A 1068 IO13048 6940680 74806170 743240613850 94.660.6 BGS
6B 90 M225-6B 29206740 2590640 3846068910 66.764.2 BGS
6B 138 M7-6B 17006330 59906430 83550610240 65.065.0 BGS
6B 138 BHN 49 40006200 67806160 11833061820 95.961.9 BHN
6B 176 M49-6B 2100620 36906330 4678066980 62.063.2 BGS
6B 176 BHN 50 1870690 5480670 9954066760 88.362.4 BHN
6B 273 JJ270-6B 11606300 1720660 2833063500 57.460.9 BGS
9V 156 BHN 62 1260690 33806100 88814610140 66.964.2 BHN
9V 162 BHN 63 10406100 43406130 4180968320 76.363.0 BHN
9V 162 BHN 69 12506290 47106880 6074467590 78.362.5 BHN
14 124 M117-14 1550630 42806140 4864063840 71.165.4 BHN
14 124 BHN 84 15206180 19606110 4522464790 52.464.2 BGS
14 162 M65-14 16606180 7906140 906061490 45.060.2 BGS
14 156 M134-14 27006220 27206300 5580068190 59.260.3 BGS
14 307 PJ581/14 28006260 43006170 3451066850 75.461.4 BGS
19F 162 BHN 100 11706120 42206980 3698064000 63.361.9 BHN
19F 236 BHN 388 18106130 42206600 73880611990 80.362.8 BHN
19F 425 BHN 97 800610 44806690 5447063950 63.762.2 BHN
19F 556 n/a 26106260 63506700 1512806800 93.565.6 BHN
23F 36 OXC-1417-23F 14506130 33006550 6708068280 55.264.1 BGS
23F 37 IOPR1592 28106220 40306240 9413069770 71.961.9 BGS
23F 277 JJ279-23 34506170 63506430 14478068240 92.365.3 BGS
23F 515 IOKOR706-5 650630 910660 2925061190 45.060.5 BGS
aFIs are expressed as arbitrary units.
bBHN, Birgitta Henriques-Normark; BGS, Brian G. Spratt.
cnot available.
doi:10.1371/journal.pone.0024581.t001
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in opaque phase. To further investigate whether variation in
capsule thickness may explain differences in C3b/iC3b deposi-
tion between strains, the capsule quantity of the 6B or 23F
serotype clinical isolates (which had marked variation in C3b/
iC3b results between strains) was assessed using the All-Stains
assay. For both serotypes there were no significant differences
between strains in the amount of polysaccharide detected. These
data were supported by EM measurement of the capsule layer
thickness for selected strains (the technique is too labour intensive
to be used for large numbers of strains) using a fixation technique
that preserves the capsule. Previously we have demonstrated that
EM can identify significant differences in capsular width between
between opaque and transparent phase variants of the same
capsular serotype [26]. EM confirmed that two serotype 6B and
two serotype 23F strains with large differences in C3b/iC3b
deposition had no significant differences in capsule thickness
(R.0.05, Fig. 3B). Furthermore FITC dextran exclusion
microscopy showed no differences in bacterial size for all the
serotype 6A, 6B and 23F strains investigated in this study (data
not shown). Hence differences in C3b/iC3b deposition between
strains of the same capsular serotype are unrelated to major
variations in capsule thickness.
Correlation of antibody recognition and C3b/iC3b
deposition results
Complement deposition on S. pneumoniae is highly dependent on
antibody recognition [12,23]. To assess whether differences in
C3b/iC3b deposition between strains could be related to
differences in recognition by naturally acquired antibody, anti-
capsular antibody levels in the serum used for the complement
assays were measured using ELISA. In addition, to measure
combined anti-capsular and anti-protein antigen antibody recog-
nition of each strain in the sera used for this study total IgG
binding was assessed using a flow cytometry assay. Although there
was some variation between serotypes, with the exception of
serotype 14, anti-capsular IgG levels were less than 1.10 mgm l
21
for each serotype (Fig. 4A) in the serum used for the complement
assays. Anti-serotype 14 levels were markedly higher at
6.44 mgm l
21; however there was no obvious relationship between
anti-capsular antibody levels and C3b/iC3b deposition. For
example serotypes 6B, 19F and 23F had very similar median
C3b/iC3b deposition results despite different levels of anti-
capsular IgG (Figs. 1 and 4A). There was also significant variation
in total IgG binding to strains within the same serotype (eg 14, 6A,
6B, 19F, and 23F) when incubated in the serum used for the
complement assays; these serotypes tended to have large variations
Figure 1. C3b/iC3b deposition in 25% human serum on clinical isolates of S. pneumoniae measured using flow cytometry and
expressed as an FI. (A) Median (IQR) FI of C3b/iC3b deposition on at least 3 clinical S. pneumoniae isolates from serotypes 1, 4, 7F, 9V, 6B, 19F and
23F. Data were analysed using the Kruskal Wallis test and showed no significant differences between serotypes shown in this panel. (B) Median FI of
C3b/iC3b deposition on clinical isolate S. pneumoniae strains of serotype 6B and 6A. P value represents the results of a Mann-Whitney U Test. (C) and
(D) Representative flow cytometry histograms of C3b/iC3b deposition on serotype 6B and 23F strains. Labels refer to strain ST.
doi:10.1371/journal.pone.0024581.g001
Streptococcus pneumoniae Complement Resistance
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e24581in C3b/iC3b deposition between strains as well. Median IgG
binding to the serotype 6A strains was significantly higher than
median IgG binding to other capsular serotypes, perhaps partially
explaining why the serotype 6A strains were particularly sensitive
to complement (Fig. 4A). Overall, total IgG binding to each strain
showed a relatively weak positive correlation with C3b/iC3b
deposition that was strongly statistically significant (Pearson’s
Correlation Co-efficient R
2=0.37, P,0.001) (Fig. 4B).
Relationships between IgG and C1q binding and C3b/
iC3b deposition results for each strain
C1q is the first component of the classical complement pathway
and binds to S. pneumoniae through antibody recognition as part of
the adaptive immune response or binding of serum proteins such
as CRP and SAP to the cell wall as part of the innate immune
response. Binding of C1q to S. pneumoniae varied markedly between
strains (Table 1 and Fig. 5), and correlated with total IgG binding.
However the correlation between C1q and total IgG binding was
weak (R
2 of 0.25, P.0.001), whereas the correlation between C1q
binding and C3b/iC3b deposition was relatively strong (R
2 0.58)
(Fig. 5). These data suggest that total IgG binding was not the only
determinant of differences in C3b/iC3b deposition between S.
pneumoniae strains and that other factors affecting C1q binding may
also be involved.
Differences in C3b/iC3b deposition between strains of
the same serotype persist in the absence of IgG
To further investigate whether differences in IgG binding are
not the only cause of variations in C3b/iC3b deposition between
strains of the same capsular serotype, the C3b/iC3b assays were
repeated for the serotype 23F and 6B strains using serum in which
the IgG had been cleaved by IdeS. IdeS totally abrogates IgG
binding to S. pneumoniae, so should remove any differences in
complement activation due to variable antibody recognition of
each strain [12,38]. As expected C3b/iC3b deposition was lower
on all strains in IdeS treated serum, and some of the differences
between strains were also reduced (eg between serotype 23F ST37
and ST515 or ST36 strains) (Fig. 6). However significant
differences between some strains with the same serotype persisted
(eg between serotype 6B ST138 and the serotype 23F ST277
strains and other strains with the same serotype, ANOVAs with
post-hoc tests R,0.01) (Fig. 6B and 6D), confirming that at least
some of the variation in C3b/iC3b results between strains of the
same serotype is not due to differences in IgG binding.
Discussion
The vital role of complement for immunity to S. pneumoniae
[1,2,3,4,10,39] suggests that differences in complement sensitivity
could affect the relative invasiveness of S. pneumoniae strains, and so
evaluating factors influencing S. pneumoniae complement resistance
is an important area of research. Data obtained using capsular
serotype switched strains has confirmed capsular serotype is one
factor that affects the sensitivity of different S. pneumoniae strains to
complement [24,25,26]. Recent data has demonstrated that there
is also a considerable amount of genetic variation between strains
within a serotype and even within strains with the same MLST
genotype [27,28,31,32,33]. We have therefore investigated the
relationship of capsule serotype and non-capsular genetic variation
Figure 2. Correlation of neutrophil association in 20% human
serum measured using flow cytometry of clinical isolates of S.
pneumoniae with the FI for C3b/iC3b deposition. Neutrophil
association results are expressed as percentage of neutrophils
associated with bacteria. Serotype 6A strains were excluded from this
correlation due to their very high level of C3b/iC3b deposition results
and their higher level of IgG binding (see Figure 4). P values and R
2 were
obtained using Pearson’s correlation test.
doi:10.1371/journal.pone.0024581.g002
Figure 3. Capsule thickness of selected S. pneumoniae clinical
isolates. (A)O D 540 for the All-Stains assay for serotype 6B and 23F S.
pneumoniae strains compared to results for the TIGR4 serotype 4 strain
(T4), the 0100993 serotype 3 strain (3), and an unencapsulated TIGR4
strain (cps
2). There were no statistically significant differences between
strains within each serotype. (B) Medians and interquartile range (IQR)
of capsule thickness (nm) measured by EM for S. pneumoniae serotypes
6B (ST 138 and 176) and 23F (ST 515 and 277). There were no
statistically significant differences between strains within each serotype.
doi:10.1371/journal.pone.0024581.g003
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tative STs for eight of the commonest serotypes that cause invasive
disease [40]. The results of the C3b/iC3b deposition assays
demonstrated that complement resistance varied markedly
between strains for some capsular serotypes (eg 6A, 6B, 19F,
23F), with less variation between strains for other serotypes (eg 1
and 4). The functional importance of these differences in C3b/
iC3b results was demonstrated by their strong positive correlation
with neutrophil association, one of the main effectors for bacterial
killing during S. pneumoniae infection.
Our data support other recently published data demonstrating
that variations in sensitivity to complement-mediated immunity
between different S. pneumoniae strains is affected by both capsular
serotype and genetic variation independent of capsular serotype
[23,24,26,34,35]. For example, Sabharwal et al. found that C3b/
iC3b deposition varied between serotype 6A strains [34] and
Melin et al. very recently demonstrated C3b/iC3b deposition
varied between strains with the same capsular serotypes [35]. Our
data support these findings but in general show larger variations
between strains for some serotypes. This may be partially due to
the slightly larger number of isolates analysed by Melin et al (6 or 7
for some serotypes), but is also likely to be partly caused by
presentation of our results as an FI rather than just using the
geometric mean MFI of C3b/iC3b deposition. FI is the product of
the proportion of bacteria positive for C3b/iC3b and the mean
intensity MFI, allowing both factors to be represented which is
important for data with a biphasic distribution (Fig. 1) [2] but
increases the range of results obtained. The large differences in
C3b/iC3b deposition results for strains with the same serotype
meant the only significant difference in median C3b/iC3b
deposition between serotypes was between serotype 6A strains
and all other serotypes. Hence our data suggest that for clinical
strains serotype-independent factors are often just as powerful
influences on C3b/iC3b deposition as capsular serotype. As well as
differences in C3b/iC3b deposition between strains with different
Figure 4. Capsular antibody levels in serum used for this study
measured using ELISAs and total IgG binding in 25% serum on
S. pneumoniae clinical isolates measured using flow cytometry.
(A) Median (IQR) FI of IgG binding on at least 3 clinical S. pneumoniae
isolates from serotypes 1, 4, 7F, 9V, 6B, 19F and 23F. For the overall
comparison between strains P,0.034 (Kruskal Wallis) and compared to
serotype 1 *P,0.05 for 6A strains only (Dunn’s post-hoc tests). Total
anti-capsular IgG levels (mgm l
21) are given above each box and
whisker plot for each serotype. (B) Correlation of the FI for IgG binding
to the FI for C3b/iC3b deposition on clinical isolates of S. pneumoniae.
Serotype 6A strains were excluded from this correlation due to their
very high level of C3b/iC3b deposition results (see Figure 1). P values
and R
2 were obtained using Pearson’s correlation test.
doi:10.1371/journal.pone.0024581.g004
Figure 5. Correlations of C1q binding to S. pneumoniae clinical
isolates in 25% human serum measured using flow cytometry.
Correlations of C1q binding to S. pneumoniae clinical isolates in 25%
human serum measured using flow cytometry to IgG binding (A) and
C3b/iC3b deposition results (B). Serotype 6A strains were excluded from
these correlations due to their very high level of C3b/iC3b deposition
results and their higher level of IgG binding (see Figure 4). P values and
R
2 were obtained using Pearson’s correlation test.
doi:10.1371/journal.pone.0024581.g005
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capsular serotype. Therefore obtaining an accurate median level of
C3b/iC3b deposition for each serotype using data obtained from a
relatively small number of representative strains is not really
possible, as using serotype and ST alone may not adequately
identify a range of representative strains. Instead comparing
phenotypes such as complement sensitivity between each capsular
serotype will require investigating a very large number of clinical
strains for each serotype or using capsular switched strains
[24,26,41].
Several mechanisms may explain variation in C3b/iC3b
deposition independent of capsular serotype. The most obvious
would be differences in capsule thickness or antibody activity
between strains, and we have investigated these possibilities for
selected strains showing large differences in C3b/iC3b deposition.
We found no differences in capsule thickness between serotype 6B
and 23F strains with large variations in sensitivity to complement,
and antibody to capsular polysaccharide should have identical
effects for strains with the same capsular serotype. Total IgG
binding, which includes binding to protein and other non-capsular
antigens that may vary in expression between strains of the same
capsular serotype, did weakly correlate with C3b/iC3b deposition.
However, large differences in C3b/iC3b deposition between some
strains with the same serotype persisted when IgG was depleted by
cleavage with IdeS [26,38], indicating that there must be
additional mechanisms affecting C3b/iC3b deposition. Serotypes
with large variations between strains in the C3b/iC3b deposition
results tended to be those that have previously been described as
more genetically diverse (eg serotypes 6A, 6B, 19F), whereas those
with less variation in C3b/iC3b results were more clonally related
(1 and 4) [42]. These data are compatible with a genetic basis for
the differences in complement sensitivity, such as allelic variation
of pspC and pspA affecting the corresponding proteins’ functions
[29,30] or differences in expression levels of genes encoding PspC,
PspA, pneumolysin and other proteins that affect complement
activity. For example, only some PspC variants bind to C4BP,
which could cause differences in sensitivity to classical pathway
(C1q dependent) immunity [18]. In addition, Factor H binding to
PspC varies between strains and we have recently demonstrated
that deletion of pspC has different effects on C3b/iC3b deposition
depending on strain background [14,43]. The large number of
RDs in the S. pneumoniae genome may contain genes that also
directly affect complement function in specific strains only, and the
surface expression of complement targets (which are largely
unknown for S. pneumoniae) could also vary between strains. Finally
there could be as yet not described small differences in capsule
structure within a serotype or additional unrecognised phase
variant phenotypes which could affect complement activity. The
close correlation between C1q binding and C3b/iC3b deposition
is compatible with differences in complement resistance between
strains being related to differences in classical pathway activation.
However, the mechanisms affecting serotype-independent differ-
Figure 6. C3b/iC3b deposition on S. pneumoniae independent of IgG. (A), (C) Mean FI of C3b/iC3b deposition measured using flow cytometry
on (A) 6B and (C) 23F clinical isolates of S. pneumoniae when incubated in untreated 25% human serum. (B), (D) Mean FI of C3b/iC3b deposition
measured using flow cytometry on (B) 6B and (D) 23F clinical isolates of S. pneumoniae when incubated in 25% human serum treated with IdeS. For all
panels, error bars represent SDs and *P,0.01 and **P,0.001 for results compared to the ST273 (A and B) and 515 (C and D) strains (ANOVAs with
post-hoc tests).
doi:10.1371/journal.pone.0024581.g006
Streptococcus pneumoniae Complement Resistance
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e24581ences in complement resistance between S. pneumoniae strains are
likely to be complex and vary between strains, making their
characterisation difficult. Investigating some of the seemingly
closely related strains (same ST and serotype) with large
differences in C3b/iC3b deposition identified by this study might
begin to characterise these mechanisms.
Given the vital role for complement in preventing systemic
infection by S. pneumoniae [2,13], differences in C3b/iC3b
deposition could account for some of the recognised differences
in invasiveness between S. pneumoniae strains. Relative invasiveness
is closely linked to capsular serotype, and serotype-dependent
differences in complement sensitivity have been correlated to
serotype-dependent variations in death rates [35]. Linking capsule-
independent genetic variation to specific infection phenotypes is
difficult due to the low proportion of total isolates that belong to
each ST. However, there are some STs that seem to be more
invasive than other STs with the same capsular serotype, and it is
possible that this could be related to serotype-independent
differences in complement sensitivity [42]. For example, transpar-
ent phase 6A strains isolated from the middle ear in patients with
otitis media were more resistant to complement than transparent
phase 6A strains isolated from the nasopharynx [34]. Although
isolation of a particular strain from the nasopharynx does not
mean it is necessarily a non-invasive isolate, these data are
compatible with the possibility that infection develops with
particular strains due to their complement resistant phenotype.
Similar data obtained for large numbers of well-characterised
strains for other common serotypes may also help to assess any
links between invasiveness and complement resistance.
To conclude, in this manuscript we have demonstrated that the
genetic background of S. pneumoniae strains caused marked
variations in opsonisation with C3b/iC3b independent of capsular
thickness or serotype. This capsule-independent variation in
complement resistance was similar in strength to capsular
serotype-dependent effects. Variation in complement resistance
was partially dependent on differences in IgG binding, but
persisted for some strains even in IgG-depleted serum and was
strongly correlated to C1q binding. These data indicate capsule-
independent genetic variation between strains affects interactions
with complement. Further investigation is required to characterise
the mechanisms causing variation in complement sensitivity
between S. pneumoniae strains and its relevance during the
development of disease.
Materials and Methods
Ethics
Human serum was obtained with written consent from healthy
human volunteers under ethical approval granted by the local
University College London ethics committee. As serum donors
were university staff, written consent was considered unnecessary.
Bacterial strains and culture conditions
S. pneumoniae strains used in these experiments from are shown in
Table 1. All strains were clinical isolates obtained from
nasopharyngeal culture of children or from invasive infection in
adults and children and were previously serotyped and assigned an
ST by MLST as described [42,44,45]. Bacteria were cultured at
37uCi n5 %C O 2 on blood agar plates or in Todd-Hewitt broth
supplemented with 0.5% yeast extract to an optical density at
580 nm of 0.4 (approximately 10
8 CFU/ml) and stored at 270uC
in 10% glycerol as single-use aliquots. Bacterial phase was
determined using transparent medium (Tryptone Soya with
catalase) under magnification and oblique, transmitted illumina-
tion as previously described [46]. Capsule quantity was deter-
mined using the All-Stains assay for acidic polysaccharides.
Bacteria grown to an optical density at 580 nm of 0.4 were
washed and resuspended in water and chloroform added. After
shaking the aqueous layer was added to All-Stains (Sigma) solution
(10 mg in 50 mls of formamide and 30 ml acetic acid) and the
optical density (OD640) measured [46].
Complement and neutrophil association assays
Pooled human serum was obtained from unvaccinated normal
human volunteers [12,26]. Sera were stored in single use aliquots
at 270uC. To remove active IgG, sera were treated as previously
described with 1% Immunoglobulin G-degrading enzyme (IdeS, a
kind gift from Drs Mattias Collin and Lars Bjo ¨rck, Lund
University) which cleaves IgG at the hinge region [38], for
45 minutes at 37uC before use. Serum levels of capsule-specific
antibody titres were measured using standardized ELISAs (http://
www.vaccine.uab.edu/ELISA%20Protocol.pdf). Briefly, serum
was mixed with an absorbent containing C-polysaccharide (C-
PS) and 22F capsular PS to neutralize antibody binding to C-PS
and other common contaminants before addition in serial
dilutions to ELISA plates previously absorbed with individual
capsular serotype antigens. Serotype specific antibody bound to
the ELISA plate was detected with anti-human IgG antibody
conjugated with alkaline phosphatase, followed by addition of the
substrate, p-nitrophenyl phosphate and reading the optical density
at 405 nm. Serum total IgG binding to S. pneumoniae using flow
cytometry and a R-phycoerythrin goat anti-human IgG (Jackson
ImmunoResearch) as described [10]. C3b/iC3b deposition and
C1q binding to S. pneumoniae were measured using previously
described flow cytometry assays and fluorescein isothiocyanate
(FITC) conjugated polyclonal anti-human C3 or anti-C1q (ICN)
[12,13,26,39]. Results of complement and IgG binding assays are
presented as a fluorescence index (FI, percentage of positive
bacteria multiplied by the geometric mean MFI of IgG or C3b/
iC3b binding) in arbitrary units [2,10]. To ensure consistent results
assays were repeated using two or more stock sources cultured at
different times for each strain. Neutrophil association was
investigated using an established flow cytometry assay, fresh
human neutrophils (10
5 per reaction) and S. pneumoniae (10
6 per
reaction) labelled with 6-carboxyfluorescein succinimidyl ester
(FAMSE; Molecular Probes) and incubated in serum (diluted in
PBS) for 20 min at 37uC [10,47]. A minimum of 10,000 cells
analyzed using flow cytometry to identify the proportion of
neutrophils associated with bacteria [39].
Electron Microscopy and FITC-Dextran exclusion
measurement of capsule width
For EM analysis of the capsule width bacteria were processed as
described by Hammerschmidt et al [48]. Briefly, mid-log phase S.
pneumoniae were incubated at 37uC for 20 mins in serum or PBS
then fixed in 1% PFA. PFA-treated bacteria were fixed twice with
2% formaldehyde and 2.5% glutaraldehyde in cacodylate buffer
containing 0.075% ruthenium red (plus 0.075 M lysine-acetate for
the first fixation only), and then with 1% osmium in ruthenium red
containing cacodylate buffer for 1 h at room temperature. Washed
samples were then dehydrated with a graded series of ethanol,
infiltrated with LRWhite acrylic resin then pure resin before the
blocks were baked in gelatin capsules, cut into ultrathin sections
and mounted on copper or nickel grids. Sections were counter-
stained with 1% aqueous uranyl acetate and 0.19 M lead citrate
before air drying and examination with a Zeiss EM 1010
transmission electron microscope (100 kV). Image J software used
to determine capsule thickness by measuring the cross-sectional
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excluding the capsule, and the areas used to calculate the capsule
layer width (assuming circularity) [12]. FITC-Dextran exclusion
measurement of bacterial size was performed as described [49],
with diameters measured for 10+ bacteria for all of the serotype
6A, 6B and 23F strains.
Statistics
C3b/iC3b deposition assays were repeated using different strain
stocks by separate laboratory workers who were unaware of any
previous results. Results for each strain were highly reproducible.
Flow cytometry data between individual strains were analysed
using unpaired Student’s T test (comparison of two samples) or
one way ANOVAs (comparisons of multiple samples) with post-
hoc tests and presented as means (SD). EM and pooled flow
cytometry data from multiple strains were compared using the
Kruskal Wallis test with Dunn’s multiple comparison test (multiple
groups) and presented as medians (IQRs). Correlations were
performed using Pearson’s correlation test.
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